Uncovering Why Some High‑Risk Individuals Never Develop Cancer
Team ATLAS investigates why certain people remain cancer-free despite strong genetic or environmental risk factors.
Cancer research has long focused on treating and understanding disease once it emerges, but a growing scientific movement is shifting attention toward an equally compelling question: why do some people never develop cancer at all? As researchers uncover patterns of resilience in individuals with high genetic or environmental risk, cancer avoidance is emerging as a frontier with profound implications for prevention and early detection.
Dr. Paul Bastard, team lead of ATLAS, a Cancer Grand Challenges initiative, is at the forefront of this effort. His team is investigating the biological signatures that distinguish individuals who remain cancer‑free despite substantial risk factors. Their work spans immunology, proteomics, and population‑scale analysis, aiming to uncover mechanisms that could reshape our understanding of cancer formation.
Technology Networks spoke with Bastard to discuss the hypotheses driving ATLAS’s research, the challenges of studying cancer avoidance, and how insights from autoantibodies and immune surveillance could unlock new diagnostic and therapeutic strategies.
Exploring the biological basis of cancer avoidance
The immune system plays a key role in cancer development, and as such, may also contribute to cancer avoidance. Autoantibodies, which are antibodies that target the body’s own proteins, are of particular interest. While often associated with autoimmune disease, they may also influence how the immune system interacts with cancer.
Team ATLAS hypothesizes that cancer is recognized by the immune system, whether it is tolerated or destroyed. As the memory of these immune interactions with cancer cells persists in serum antibodies, identifying the autoantibodies involved in an active immune response against cancer may hold the key to understanding why some people don’t develop cancer.
Autoantibodies could enhance immune surveillance, enabling the body to detect and eliminate emerging cancer cells before they progress. Some antibodies may directly target tumor‑associated antigens, acting as a natural defense mechanism. “They might change the immune response against cancer, or target cancer avoidance mechanisms,” explained Bastard. “Antibodies targeting cancer cells might also be able to fend them off.”
On the other hand, certain populations of more cancer-permissive autoantibodies might enable tumor development. In essence, differences in antibody profiles may account for variations in cancer risk.
Key mechanisms shaping cancer resilience:
- Autoantibodies may enhance immune surveillance against early‑stage cancer cells.
- Some antibodies could directly recognize and neutralize tumor‑associated targets.
- Understanding natural resilience may shift cancer research toward prevention.
Overcoming the challenges of studying cancer avoidance
Studying cancer avoidance requires analyzing individuals who have not developed disease—a fundamentally different approach from traditional oncology research. “By uncovering what makes these people resistant, we hope ATLAS’s work as part of Cancer Grand Challenges has the potential to change how we think about cancer formation and transform cancer prevention,” said Bastard.
He noted that identifying these individuals at scale is difficult, and understanding how they avoided cancer demands comprehensive molecular profiling.
“Without the unique global team science mechanisms from Cancer Grand Challenges, doing this research at this scale would not be possible,” he explained.
Accelerate your PROTACs drug discovery and development
This eBook shows how an integrated, end-to-end analytical approach helps labs generate reliable, regulatory-ready PROTAC data at every stage of development.View eBook
ATLAS is addressing this challenge by conducting unbiased, proteome‑wide analyses across large cohorts. This approach allows the team to compare individuals who developed cancer with those who remained cancer‑free, revealing patterns in autoantibody populations that would be invisible in smaller datasets.
Scaling cancer avoidance research:
- Large‑scale proteomic profiling is essential to detect subtle biological differences.
- Cancer avoidance studies require collaboration and shared datasets.
- Comparing avoiders and cancer‑developing individuals reveals mechanistic clues.
Identifying cancer-protective biological pathways
ATLAS focuses on individuals who remain cancer‑free despite significant risk factors. These include carriers of high‑risk mutations in genes such as BRCA, people of advanced age, and individuals with heavy exposure to carcinogens like tobacco or alcohol.
Bastard explained that these individuals represent a rare but scientifically invaluable population. “We have selected individuals who have remained cancer‑free despite having genetic risk factors or high‑risk exposure,” he noted.
These “extreme phenotypes” provide a unique window into biological resilience.
Advancing RNA Delivery Beyond Vaccines
This eBook explores key scientific advances in LNP development that are shaping the future of RNA delivery, including repeat dosing, lyophilization, harnessing multi-antigen mRNA, and organ-specific targeting.View eBook
By comparing people with extreme phenotypes to cohorts of patients with diverse cancer types, the team aims to uncover protective mechanisms that counteract genetic or environmental risk.
Profiling cancer‑resistant individuals:
- ATLAS studies people who remain cancer‑free despite strong risk factors.
- These “extreme phenotypes” may reveal protective biological pathways.
- Comparing risk‑exposed cancer-avoiders with cancer patients will highlight resilience mechanisms.
- Insights may inform new models of cancer susceptibility.
Translating cancer avoidance into new interventions
If protective mechanisms can be identified, they could be harnessed to develop new therapies, early‑detection biomarkers, or even preventive interventions.
One promising avenue is antibody‑based strategies. ATLAS hopes to identify beneficial antibodies that could be administered therapeutically, while also recognizing harmful ones that may need to be removed. “Ultimately, we hope to produce and administer good antibodies and, by contrast, remove bad ones for both cancer prevention and treatment,” Bastard explained.
Potential clinical applications:
- Protective antibodies could inspire new immunotherapies.
- Removing harmful antibodies could reduce cancer risk.
- Cancer avoidance mechanisms may guide next‑generation prevention strategies.
Cell and Gene Therapies: The Evolution of Advanced Biologics
This eBook takes a look at the challenges shaping advanced biologics, alongside practical strategies to improve consistency, scalability, and compliance across development and manufacturing.View eBook
Mapping antibody signatures of cancer resistance
ATLAS is deploying “very powerful and large techniques, which allow us to look for >21,000 auto-antibodies and many more antibodies against cancer targets,” Bastard explained. This scale enables the team to detect patterns linked to tumor suppression, tumor promotion, or specific environmental exposures.
Bastard emphasized that these powerful platforms allow for unprecedented resolution in mapping antibody repertoires. By integrating these data with clinical and exposure histories, ATLAS aims to validate which antibodies truly contribute to cancer avoidance.
Decoding antibody‑based biomarkers:
- High‑throughput platforms enable screening of tens of thousands of antibodies.
- Antibody signatures may distinguish anti‑tumor from pro‑tumor responses.
- Validated biomarkers may guide prevention and early detection.
Researchers are increasingly recognizing that cancer avoidance—remaining cancer‑free despite significant risk—offers a powerful lens for understanding disease biology. Bastard and the ATLAS team are pioneering this field through large‑scale proteomic analysis, immune profiling, and antibody discovery. Their work suggests that autoantibodies and enhanced immune surveillance may underpin natural resistance to cancer.
By identifying and validating these mechanisms, ATLAS aims to translate biological resilience into new diagnostic, therapeutic, and preventive strategies.
Key takeaways:
- Cancer avoidance is emerging as a critical frontier for prevention‑focused oncology.
- Autoantibodies may enhance immune surveillance and contribute to natural cancer resistance.
- ATLAS studies individuals who remain cancer‑free despite high genetic or environmental risk.
- Insights from avoidance mechanisms could inform new therapies and early‑detection tools.
This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
